Power calculations were conducted based on the approximation that the sample size for a MR study is the sample size for exposure on outcome divided by the r 2 for genetic proxies on exposure [38, 39]
Whether FcRn antagonists in the clinical pipeline may have similar effects and thereby could be viable prophylactic treatment options for viral infection is still an open question, given that they are, in most cases, selected to specifically engage and occlude the binding site of IgG on FcRn
developed vitamin C-lipid supramolecular nanoassemblies and demonstrated in DSS-induced colitis mice that this strategy significantly ameliorated disease severity, reduced inflammatory burden, and reshaped the gut microbial profile, thereby suggesting a potential role for vitamin-based interventions in modulating intestinal inflammation and microbiota homeostasis 206
GMP ISO 17034:2016 - ZPHC
Key Takeaways GLP-1 receptor agonists have evolved from diabetes medications into essential cardiovascular drugs, offering proven protection against heart attacks, strokes, and cardiovascular death across diverse patient populations
therefore, therapeutic interventions should be earlier and more intensive in these groups
